Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging - PubMed (original) (raw)
Review
. 2004 Apr;45(4):594-607.
Affiliations
- PMID: 15073255
Free article
Review
Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging
Daniel H S Silverman. J Nucl Med. 2004 Apr.
Free article
Abstract
The clinical identification and differential diagnosis of dementias is especially challenging in the early stages, but the need for early, accurate diagnosis has become more important, now that several medications for the treatment of mild to moderate Alzheimer's disease (AD) are available. Many neurodegenerative diseases produce significant brain-function alterations detectable with PET or SPECT even when structural images with CT or MRI reveal no specific abnormalities. (18)F-FDG PET images of AD demonstrate focally decreased cerebral metabolism involving especially the posterior cingulate and neocortical association cortices, while largely sparing the basal ganglia, thalamus, cerebellum, and cortex mediating primary sensory and motor functions. Assessment of the precise diagnostic accuracy of PET had until recently been hindered by the paucity of data on diagnoses made using PET and confirmed by definitive histopathologic examination. In the past few years, however, studies comparing neuropathologic examination with PET have established reliable and consistent accuracy for diagnostic evaluations using PET-accuracies substantially exceeding those of comparable studies of the diagnostic value of SPECT or of both modalities assessed side by side, or of clinical evaluations done without nuclear imaging. Similar data are emerging concerning the prognostic value of (18)F-FDG PET. Improvements in the ability of PET to identify very early changes associated with AD and other neurodegenerative dementias are currently outpacing improvements in therapeutic options, but with advances in potential preventive and disease-modifying treatments appearing imminent, early detection and diagnosis will play an increasing role in the management of dementing illness.
Similar articles
- A comparison of FDG-PET and blood flow SPECT in the diagnosis of neurodegenerative dementias: a systematic review.
Davison CM, O'Brien JT. Davison CM, et al. Int J Geriatr Psychiatry. 2014 Jun;29(6):551-61. doi: 10.1002/gps.4036. Epub 2013 Oct 9. Int J Geriatr Psychiatry. 2014. PMID: 24123413 Review. - 18F-FDG PET Improves Diagnosis in Patients with Focal-Onset Dementias.
Taswell C, Villemagne VL, Yates P, Shimada H, Leyton CE, Ballard KJ, Piguet O, Burrell JR, Hodges JR, Rowe CC. Taswell C, et al. J Nucl Med. 2015 Oct;56(10):1547-53. doi: 10.2967/jnumed.115.161067. Epub 2015 Aug 6. J Nucl Med. 2015. PMID: 26251415 - European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus.
Nobili F, Arbizu J, Bouwman F, Drzezga A, Agosta F, Nestor P, Walker Z, Boccardi M; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. Nobili F, et al. Eur J Neurol. 2018 Oct;25(10):1201-1217. doi: 10.1111/ene.13728. Epub 2018 Jul 20. Eur J Neurol. 2018. PMID: 29932266 - Brain PET in suspected dementia: patterns of altered FDG metabolism.
Brown RK, Bohnen NI, Wong KK, Minoshima S, Frey KA. Brown RK, et al. Radiographics. 2014 May-Jun;34(3):684-701. doi: 10.1148/rg.343135065. Radiographics. 2014. PMID: 24819789 Review.
Cited by
- Early-phase amyloid PET reproduces metabolic signatures of cognitive decline in Parkinson's disease.
Aye WWT, Stark MR, Horne KL, Livingston L, Grenfell S, Myall DJ, Pitcher TL, Almuqbel MM, Keenan RJ, Meissner WG, Dalrymple-Alford JC, Anderson TJ, Heron CL, Melzer TR. Aye WWT, et al. Alzheimers Dement (Amst). 2024 Jun 22;16(2):e12601. doi: 10.1002/dad2.12601. eCollection 2024 Apr-Jun. Alzheimers Dement (Amst). 2024. PMID: 38912306 Free PMC article. - A deep learning model for generating [18F]FDG PET Images from early-phase [18F]Florbetapir and [18F]Flutemetamol PET images.
Sanaat A, Boccalini C, Mathoux G, Perani D, Frisoni GB, Haller S, Montandon ML, Rodriguez C, Giannakopoulos P, Garibotto V, Zaidi H. Sanaat A, et al. Eur J Nucl Med Mol Imaging. 2024 Oct;51(12):3518-3531. doi: 10.1007/s00259-024-06755-1. Epub 2024 Jun 11. Eur J Nucl Med Mol Imaging. 2024. PMID: 38861183 Free PMC article. - SPECT/CT and PET/CT, related radiopharmaceuticals, and areas of application and comparison.
Alqahtani FF. Alqahtani FF. Saudi Pharm J. 2023 Feb;31(2):312-328. doi: 10.1016/j.jsps.2022.12.013. Epub 2022 Dec 30. Saudi Pharm J. 2023. PMID: 36942267 Free PMC article. Review. - 18F-FDG PET and a classifier algorithm reveal a characteristic glucose metabolic pattern in adult patients with moyamoya disease and vascular cognitive impairment.
Weng R, Ren S, Su J, Ni W, Yang C, Gao X, Xiao W, Zhang X, Jiang H, Guan Y, Huang Q, Gu Y. Weng R, et al. Brain Imaging Behav. 2023 Apr;17(2):185-199. doi: 10.1007/s11682-022-00752-4. Epub 2023 Jan 13. Brain Imaging Behav. 2023. PMID: 36637715 - Functional Correlates of Striatal Dopamine Transporter Cerebrospinal Fluid Levels in Alzheimer's Disease: A Preliminary 18F-FDG PET/CT Study.
Camedda R, Bonomi CG, Di Donna MG, Chiaravalloti A. Camedda R, et al. Int J Mol Sci. 2023 Jan 1;24(1):751. doi: 10.3390/ijms24010751. Int J Mol Sci. 2023. PMID: 36614193 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous